This suggests that MGO accumulation in ovarian cancer may serve a protective role when BRCA2 is impaired, potentially impacting BRCA2 function and influencing ovarian cancer progression through Glo1 regulation. This evidence concerns the gene GLO1 and ovarian cancer.